The Lancet, 398(10306), 1157-1169. Elsevier Limited The Lancet, 398(10306), 1157-1169. Elsevier Ltd. Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8 Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma : an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8 Hutchings, M, Mous, R, Clausen, M R, Johnson, P, Linton, K M, Chamuleau, M E D, Lewis, D J, Sureda Balari, A, Cunningham, D, Oliveri, R S, Elliott, B, DeMarco, D, Azaryan, A, Chiu, C, Li, T, Chen, K M, Ahmadi, T & Lugtenburg, P J 2021, ' Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study ', The Lancet, vol. 398, no. 10306, pp. 1157-1169 . https://doi.org/10.1016/S0140-6736(21)00889-8